TRCT
SNTI icon

Tower Research Capital (TRC)’s Senti Biosciences Holdings SNTI Stock Holding History

Tower Research Capital (TRC)’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.08K Buy
+7,344
New +$7.18K ﹤0.01% 4098
2026
Q1 		– Sell
-3,411
Closed -$3.55K – 5528
2025
Q4 		$3.55K Buy
3,411
+1,681
+97% +$2.97K ﹤0.01% 4354
2025
Q3 		$2.44K Buy
1,730
+609
+54% +$1.02K ﹤0.01% 4631
2025
Q2 		$2.37K Sell
1,121
-304
-21% -$962 ﹤0.01% 4660
2025
Q1 		$4.79K Buy
1,425
+402
+39% +$1.56K ﹤0.01% 4197
2024
Q4 		$3.59K Sell
1,023
-1,336
-57% -$4.26K ﹤0.01% 4632
2024
Q3 		$5.33K Buy
2,359
+1,977
+518% +$5.22K ﹤0.01% 4291
2024
Q2 		$1.05K Sell
382
-469
-55% -$1.52K ﹤0.01% 5216
2024
Q1 		$3.21K Buy
+851
New +$3.8K ﹤0.01% 4903
2023
Q3 		– Sell
-338
Closed -$2.12K – 6200
2023
Q2 		$2.12K Buy
+338
New +$3.3K ﹤0.01% 5246
2023
Q1 		– Sell
-2,308
Closed -$33K – 6246
2022
Q4 		$33K Buy
2,308
+1,363
+144% +$33.2K ﹤0.01% 2670
2022
Q3 		$21K Buy
945
+822
+668% +$16.2K ﹤0.01% 3905
2022
Q2 		$2K Buy
123
+52
+73% +$4.18K ﹤0.01% 5602
2022
Q1 		$7K Sell
71
-1
-1% -$99 ﹤0.01% 4763
2021
Q4 		$7K Buy
+72
New +$7.18K ﹤0.01% 4940

Other funds holding SNTI

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
MVM
Menlo Ventures Management Menlo Park, California $357M AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s SNTI Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Senti Biosciences Holdings (SNTI) in Q2 2026: 7,344 shares worth $8.08K. The stake represents ﹤0.01% of the portfolio and ranks #4098 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in SNTI as recently as Q4 2025.

Tower Research Capital (TRC) first reported a position in SNTI in Q4 2021 and has held it in 15 quarters since. The position peaked at $33K in Q4 2022. 17 funds tracked by Wall St. Rank hold SNTI as of Q2 2026.

  • Tower Research Capital (TRC) held 7,344 shares of Senti Biosciences Holdings worth $8.08K as of Q2 2026.
  • Senti Biosciences Holdings was a new Tower Research Capital (TRC) position in Q2 2026.
  • Senti Biosciences Holdings made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4098 holding.
  • Tower Research Capital (TRC) first reported a position in Senti Biosciences Holdings in Q4 2021 and has held it in 15 quarters since.
  • Tower Research Capital (TRC)'s Senti Biosciences Holdings position peaked at $33K in Q4 2022.
  • 17 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.